Paris, December 20th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the appointment of Dr Yannick Plétan as Chief Medical Officer. He will report to Gilles Avenard, CEO of Acticor Biotech and be responsible for […]
Press Releases
January 20, 2018
Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
October 18, 2017
Acticor Biotech first-in-human clinical trial in healthy volunteers
Paris, October 17th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and myocardial infarction, today announced the agreement of Dutch Authorities for the initiation of a phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized fragment of […]
May 19, 2017
Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum
Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum Phase 1 to start in October 2017 Paris, May 18th, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, announced today that it has received its second payment from Mediolanum, triggered by […]
February 23, 2017
Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I
The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Paris, February 23rd, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 […]
February 7, 2017
Acticor Biotech Secures €1,5M new funding from CapDecisif Management
To accelerate the clinical study of ACT-017, for the emergency treatment of stroke Paris, February 7th 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total […]
October 14, 2016
Stroke company Acticor Biotech and Mediolanum announce a Research Collaboration Agreement
For ACT017, a « first in class » antithrombotic treatment for Acute Ischemic Stroke. Paris, Milan, on October 14, 2016 – Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum […]